PTEN and neoplasm: AZD8186, a selective PI3Kβ/δ inhibitor, has shown anti-tumor activity in PTEN-deficient preclinical models, and has undergone clinical testing among patients with advanced solid cancers including gastric cancer (Choudhury et al., 2022; Suh et al., 2023).